Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry ; volume:34 ; number:4 ; day:21 ; month:7 ; year:2020 ; pages:529-539 ; date:8.2020
BioDrugs ; 34, Heft 4 (21.7.2020), 529-539, 8.2020
- Creator
-
Kim, Hyoun-Ah
Lee, Eunyoung
Lee, Sun-Kyung
Park, Yong-Beom
Shin, Kichul
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-020-00432-z
- URN
-
urn:nbn:de:101:1-2020092521365031303485
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Hyoun-Ah
- Lee, Eunyoung
- Lee, Sun-Kyung
- Park, Yong-Beom
- Shin, Kichul
- SpringerLink (Online service)
Other Objects (12)
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
Rheumatology
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
Rheumatology
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
What is the future of targeted therapy in rheumatology: biologics or small molecules?
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review